Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

HYPMET Hyperpolarized Magnetic Resonance at the point-of-care

Coordinator
Universita Degli Studi Di Padova, Italy
Runs
1 May 2024 to 30 April 2029
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101117082

What the project is doing

In the project's own words, from its summary on CORDIS.

HYPMET proposes a pioneering research methodology for hyperpolarized magnetic resonance for real-time monitoring of upregulated metabolic pathways in cancer cells and in-vivo and for body fluid metabolic analyses with the prospect of revolutionizing the medical approach to personalised treatments. A common analytical method for structural biology, medical imaging, and chemical analysis is nuclear magnetic resonance (NMR), which is flexible but intrinsically insensitive.

Even in the most sensitive NMR spectra, many endogenous compounds found in blood, saliva, or urine are currently unresolved. HYPMET will establish a ground-breaking technology enabling the detection of body fluids metabolites below the current limit of NMR detection (~μM) and the real-time monitoring of clinically relevant metabolic pathways in-cells and in-vivo; it will enable NMR metabolomics analyses at the point-of-care and will be fully compatible with personalised medical treatments; it will be compact (less than 10×10×30 cm) and will not require superconducting magnets.

Emerging methods (e.g. hyperpolarisation methods - HM) can boost the NMR signal intensity. HYPMET will merge two HMs to achieve NMR signal enhancements of several thousand-fold continuously, in the liquid state and at ultra-low-magnetic field (ULF, i.e. <10 mT) for many nuclear isotopes. The two HMs are: Overhauser Dynamic Nuclear Polarization (ODNP) and Signal Amplification By Reversible Exchange (SABRE). The PI unique expertise spans method development on various HMs and development and implementation of a protocol for real-time monitoring of pyruvate to lactate conversions in-cells and in-vivo to probe the state of a tumor in real-time.

Success in this multidisciplinary project will pave the way for efficient NMR metabolomics analyses and for better real-time metabolic conversion monitoring directly at the point-of-care. In the future, the technology could be further reduced in size and become a widespread clinical tool.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di PadovaPadovaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI